Literature DB >> 3917679

High-density lipoprotein and its apolipoproteins inhibit cytolytic activity of complement. Studies on the nature of inhibitory moiety.

C H Packman, S I Rosenfeld, J P Leddy.   

Abstract

Human high-density lipoprotein (HDL) and its apolipoproteins A-I and A-II inhibit complement-mediated lysis of human and sheep erythrocytes. This inhibitory activity under study is exerted after C9 is bound to membrane-associated C5b-8 complexes but prior to completed assembly and insertion of the C5b-9 complex. In this paper, we define some structure-activity relationships of the inhibitory moiety. With the exception of weak lytic inhibitory activity found in LDL/VLDL pools and in some unconcentrated minor fractions of plasma obtained by hydrophobic chromatography, all inhibitor activity was found in fractions which contained either apolipoprotein A-I, apolipoprotein A-II, or both. Intact HDL has a high level of inhibitor activity but delipidation by chloroform-methanol extraction was associated with an increase in activity on a protein-weight basis. Purified apolipoprotein A-I and apolipoprotein A-II exhibited equal inhibitory activity, greater than that exhibited by intact HDL. Nevertheless, ultracentrifugal fractions in which no free apolipoproteins could be demonstrated still possessed inhibitory activity. These experiments suggest that delipidation of HDL is not necessary for expression of inhibitor activity, although we could not rule out the possibility that apolipoproteins in dynamic equilibrium with HDL are responsible for the inhibitor activity observed in whole serum and plasma and in HDL preparations. Limited proteinase digestion completely abolished the inhibitory activity of partially delipidated HDL. Phospholipase C had little or no effect on the inhibitory activity of delipidated HDL, apolipoprotein A-I or apolipoprotein A-II, but reduced the inhibitory activity of intact HDL. These data suggest that the phospholipid polar headgroups are not necessary for inhibitory activity. However, the loss of these headgroups is associated with decreased activity, possibly due to increased hydrophobicity of HDL, or increased association among HDL micelles, and subsequent decrease in effective molar concentration of the inhibitory moiety.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3917679     DOI: 10.1016/0005-2736(85)90527-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Apolipoprotein A-I exerts bactericidal activity against Yersinia enterocolitica serotype O:3.

Authors:  Marta Biedzka-Sarek; Jari Metso; Andreas Kateifides; Taru Meri; T Sakari Jokiranta; Artur Muszyński; Joanna Radziejewska-Lebrecht; Vassilis Zannis; Mikael Skurnik; Matti Jauhiainen
Journal:  J Biol Chem       Date:  2011-09-06       Impact factor: 5.157

3.  Complement Factor H Binds to Human Serum Apolipoprotein E and Mediates Complement Regulation on High Density Lipoprotein Particles.

Authors:  Karita Haapasalo; Kok van Kessel; Eija Nissilä; Jari Metso; Tiira Johansson; Sini Miettinen; Markku Varjosalo; Juha Kirveskari; Pentti Kuusela; Angelika Chroni; Matti Jauhiainen; Jos van Strijp; T Sakari Jokiranta
Journal:  J Biol Chem       Date:  2015-10-14       Impact factor: 5.157

4.  The terminal complement proteins C5b-9 augment binding of high density lipoprotein and its apolipoproteins A-I and A-II to human endothelial cells.

Authors:  K K Hamilton; P J Sims
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

5.  High-density lipoproteins can act as carriers of glycophosphoinositol lipid-anchored CD59 in human plasma.

Authors:  A Väkevä; M Jauhiainen; C Ehnholm; T Lehto; S Meri
Journal:  Immunology       Date:  1994-05       Impact factor: 7.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.